Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. COPENHAGEN ...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline ...

The following is a summary of “Transcriptomic insights into early mechanisms underlying post-chikungunya chronic inflammatory ...

The European Commission (EC) has authorised the marketing of Bavarian Nordic's Vimkunya - the first chikungunya vaccine ...

Five people have been hospitalized with cardiac and neurological symptoms after getting the chikungunya vaccine.

Bavarian Nordic, a Danish biotechnology company specializing in vaccine development, was on 28 February 2025 granted ...

If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and ...

Valneva (VALN) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive ...

The US Centers for Disease Control and Prevention is currently investigating five hospitalizations that occurred in people ...